anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1319998 Spiro-benzocyclone acetic acids ROUSSEL UCLAF 4 Sept 1970 [5 Sept 1969] 42544/70 Heading C2C Novel compounds of the Formula I wherein R is hydrogen or a C 1-4  straight or branched alkyl, R 3  is hydrogen, chlorine, C 1-4  alkoxy or trifluoro methyl, Y is methylene, oxygen or sulphur and n is 2, 3 or 4, esters and salts thereof may be prepared by (1) reducing the keto group of compound II to a methylene group, (2) hydrogenating a compound III wherein X is oxygen or methylene and optionally thereafter converting the compound I wherein R is hydrogen to an ester thereof, and treating the ester with an alkylating agent to form I wherein R is C 1-4  alkyl. The intermediate III may be prepared by dehydration of the compound IV which in turn is produced by reduction of the compound II wherein Y is oxygen or methylene. The intermediate II may be prepared by (1) cyclizing a compound V (2) hydrolysing a compound XI or (3) hydrolysing a compound XVIII The intermediate V may be prepared by hydrolysis of a compound VI wherein R 4  and R 5  are the same or different and are C 1-6  alkyl or together with the adjacent nitrogen form a heterocyclic ring. The compound VI may be prepared by reacting a compound VII with sulphur and R 4 R 5 NH the compound VII wherein n is 3 or 4 being produced by chain extension of the compound wherein n is 2 or 3, the compound VII wherein n is 2 being produced by decarboxylation of the hydrolysis product of compound VIII wherein R<SP>11</SP> is a ketal group and R<SP>111</SP> is an alkyl group, the compound VIII being prepared by an alkyl cyanoacetate IX with a ketal X Alternatively the intermediate V, wherein Y is oxygen or methylene, may be produced by hydrolysis of compound XII the compound XII wherein n is 3 or 4 being produced by chain extension of XII wherein n is 2 or 3, the compound XII wherein n is 2 being prepared by reacting compound XIII wherein Hal is chlorine or bromine, with an alkali metal cyanide, the compound XIII being produced by brominating or chlorinating compound XIV which is produced by decarboxylating the hydrolysis product of compound XV which in turn is produced via an appropriately substituted Grignard reagent similar to compound VIII. The intermediate XI may be prepared by cyclizing compound XII under hydrolysing conditions. The intermediate XVIII may be prepared by reacting a compound XIX wherein Hal is chlorine or bromine with alkali metal cyanide, the compound XIX being produced by halogenation and cyclization in either order preceded by chain extension if necessary of XIV, similarly to the previously described processes. Pharmaceutical compositions of the compounds I show anti-inflammatory and analgesic activity and may be mixed with the usual excipients or further ingredients having analogous activity and administered orally, parenterally, rectally, permucosally or topically.
In humans, sleep is an essential physiological process for life and survival. The main objective of the current study is to determine the behavioural sleep patterns and social jetlag in elderly adults. The second objective is to define the relationship among subjective sleep quality, mid-sleep timings, social jetlag, and sunlight exposure. We recruited 945 female and 1047 male participants aged ≥ 60 years from 65 rural villages in the Sambalpur district of Odisha, India. The Munich Chrono Type Questionnaire (MCTQ) is a self-reported questionnaire that measures a person's behavioral sleep variables, including social jetlag and chronotype, whereas the Pittsburgh Sleep Quality Index (PSQI) measures the subjective sleep quality of an individual. We employed MCTQ and PSQI to obtain behavioral sleep variables and subjective sleep quality in the recruited subjects. The behavioral sleep variables were compared using a paired t-test on both work and work-free days. In addition, the behavioral sleep variables as a function of gender were compared using an independent Student's t-test. In the current study, most of the elderly individuals reported both midpoint of sleep on workdays (MSW) and midpoint of sleep on work-free days (MSF) between 00:01-03:00. The averages of mid-sleep timings between workdays and work-free days were not statistically significant. Data on MSFsc (midpoint of sleep on work-free days sleep corrected) indicated that most elderly adults (99.6%) are morning type; they go to bed early and wake up early. The elderly participants from the rural population of Sambalpur district in western Odisha had the least social jetlag and exhibited good subjective sleep quality. It would be worthwhile to find out the determinants of these positive features apropos social jetlag and behavioural sleep patterns.
FIELD: medicine, cosmetology, pharmacy. SUBSTANCE: invention relates to agent used for treatment of sensitive skin, to composition containing an agent for treatment of sensitive skin and to method of skin treatment. Invention relates to use of antagonist CGRP as a component of composition containing cosmetically, dermatologically or pharmaceutically acceptable medium for treatment of sensitive skin, in part, for prophylaxis and/or counteraction to irritations on skin, and/or to lichens, and/or to erythemas, and/or dysesthesic senses, and/or burning sense, and/or skin itch, and/or itch on mucosa. Antagonist CGRP ensures to effect on symptoms of neurogenous origin arising from effect of external agent that is able to modify biochemical and biophysical indices of cutaneous tissues. EFFECT: enhanced effectiveness of agent and composition, valuable medicinal properties. 16 cl, 11 ex
INTRODUCTION: The World Health Organization has reported submersion injuries as the third most common cause of death due to unintentional injury in the world. Greater detail in the rates, risk factors, and healthcare associated costs of submersion injuries could be instrumental in demonstrating the need for further funding and intervention.
METHODS: The study was a cross-sectional analysis of a nationally representative dataset of inpatient and emergency department (ED) encounters between 2006 and 2015 in the United States (US). Healthcare utilization costs were provided within the datasets and adjusted to reflect actual charges and provider fees. Lastly, the final cost values were adjusted to the 2020 US dollar (USD) and summarized using a log adjusted mean.
RESULTS: On average, there were 11,873 submersion injuries per year that presented to the ED in the US. Resulting in a rate where approximately 9 out of every 100,000 ED visits were associated with a submersion injury. Slightly more than 6% died in the ED, 24.2% were admitted, and 69.3% were discharged from the ED. In total, annual cost of submersion injuries in the US for ED care is approximately $12.5 million, inpatient care is approximately $27.5 million, and total annual healthcare cost exceeds $40 million.
DISCUSSION: While these results only represent a fraction of the total cost associated with submersion injuries, it remains substantial and unchanged over the 10-year study period. Certain demographic groups showed higher rates of injury and disease burden, thus bearing a greater amount of the cost.
Applicants have discovered a number of peptides that are capable of dose-dependent phosphorylation of ribosomal protein S6(rpS6) in a range of concentrations in an in vitro cellular assay. RPS6 is a key substrate for protein kinases and is phosphorylated by growth factors and mitogens during cell growth and cell division. This is a key step in the synthesis of new proteins in skeletal muscle tissue. The described peptides are also able to reduce the expression of mRNA transcripts (TRIM63 and FBXO32) directly linked to increased protein degradation leading to progressive skeletal muscle atrophy. In addition, increased muscle wasting is associated with a systemic elevation of circulating TNF α. The peptides described herein also result in reduced expression of TNF α in circulating immune cells. The peptides can be used to promote muscle growth and muscle health in subjects exhibiting muscle atrophy, such as elderly subjects, physically inactive persons, and subjects with indications characterized by muscle atrophy (i.e., MS and polio).
NEW MATERIAL:2-Azetidinone derivatives of formula I (R is H, lower alkyl, cycloalkyl, 2-oxoazetidinyl; R' is phenyl, thienyl, phridyl, isoxazole, where they may substituted with halogen atoms or lower alkyls). EXAMPLE:E-3-[(2-Oxoazetidin-4-yl)thio]-3-methylthio-1-phenyl-2-propen- 1-one. USE:medicine: they have antibiotic activity as well as inhibition activity against beta- lactamase. They also are used as a synthetic intermediate for compounds having the same activities. The combined use with penicillin and cephalosporin antibiotics increases the antimicrobial activity. CONSTITUTION:The reaction of 4-acyloxyazetidin-2-one of formula II with a dithio compound of formula III is effected in the presence of an alkali hydroxide to give the compound of formula I.
FIELD: medicine, therapy, pharmacy. SUBSTANCE: invention relates to treatment of patients with different diseases and involves administration of activated forms of superlow doses of antibodies raised to antigen. The latter takes part in mechanisms of development of pathological process and this substance can be both endogenous factors inducing disease and medicinal agents used for treatment of patients with this disease. Activated forms of antibodies are prepared by homeopathic technology. Invention proposes the medicinal agent containing these antibodies. Invention provides the reproduction of antigen activity in modified form promoting to reduction of pathological process and without adverse effects of treatment. EFFECT: improved method of treatment. 12 cl
In the non-VR group, the standard anesthesia procedure will be followed. Brachial plexus nerve block will be performed with a 50mm peripheral block needle (Vygon echoplex+ 22Gx50mm) with a mixture of 2% lidocaine and 0.5% bupivacaine (10 mL each) prepared as 20ml. After waiting for a sufficient time, the nerve block effectiveness of the patients will be measured by Modified Broomage scale and pinprick. Additional sedative agents may be applied to both groups at the discretion of the anesthesiologist and will be recorded. Anesthesia management will be applied to both groups in accordance with the standard working order of the Anesthesia clinic.
The invention relates to the field of a preparation method and technology of Chinese patent medicines. The invention provides an improved preparation method of notoginseng root capsules for dysmenorrhoea. The preparation method comprises the following steps: (1) individual ultra-fine pulverization is carried out for notoginseng roots, flying squirrel feces, typha pollen, corydalis tubers, Szechuan lovage rhizomes, common aucklandia roots, fennel, and borneol, in order to obtain fine powder, and the powder is uniformly mixed for standby; (2) medicinal powder obtained in the step (1) and a filler are uniformly mixed according to a weight ratio 0.5-1.5:0.5, a wetting agent is added, and granulation is carried out by extrusion with a wet method; (3) particles obtained in the step (2) are dried in a baking oven at 60 DEG C for 60 minutes, dried particles are obtained, particles are arranged and contained in capsules, and the capsules are obtained. The filler comprises starch, dextrin and lactose according to a weight proportion 7:1:1. The wetting agent comprises an ethanol alcohol whose weight percentage is 70% and a povidone solution whose weight percentage is 3%. The preparation method improves fluidity of products, solves the sticking problem, shortens disintegration time limit, and improves bioavailability.
Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
Tofacitinib was given at the dose of 10mg daily through the 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the GC daily dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
BACKGROUND: Periprosthetic joint infection (PJI) is a common source of failure following elbow arthroplasty. Perioperative prophylactic antibiotics are considered standard of care. However, there are no data regarding the comparative efficacy of various antibiotics in the prevention of PJI for elbow arthroplasty. Previous studies in shoulder, hip, and knee arthroplasty have demonstrated higher rates of PJI with administration of non-cefazolin antibiotics. The elbow has higher rates of PJI than other joints. Therefore, this study evaluated whether perioperative antibiotic choice affects rates of PJI in elbow arthroplasty.
MATERIALS AND METHODS: A single-institution, prospectively collected total joint registry database was queried to identify patients who underwent primary elbow arthroplasty between 2003 and 2021. Elbows with known infection prior to arthroplasty (25) and procedures with incomplete perioperative antibiotic data (7) were excluded, for a final sample size of 603 total elbow arthroplasties and 19 distal humerus hemiarthroplasties. Cefazolin was administered in 561 elbows (90%) and non-cefazolin antibiotics including vancomycin (32 elbows, 5%), clindamycin (27 elbows, 4%), and piperacillin/tazobactam (2 elbows, 0.3%) were administered in the remaining 61 elbows (10%). Univariate and multivariate analyses were conducted to determine the association between the antibiotic administered and the development of PJI. Infection-free survivorship was estimated using the Kaplan-Meier method.
RESULTS: Deep infection occurred in 47 elbows (7.5%), and 16 elbows (2.5%) were diagnosed with superficial infections. Univariate analysis demonstrated that patients receiving non-cefazolin alternatives were at significantly higher risk for any infection (hazard ratio [HR] 2.6, 95% confidence interval [CI] 1.4-5.0; P < .01) and deep infection (HR 2.7, 95% CI 1.3-5.5; P < .01) compared with cefazolin administration. Multivariable analysis, controlling for several independent predictors of PJI (tobacco use, male sex, surgical indication other than osteoarthritis, and American Society of Anesthesiologists score), showed that non-cefazolin administration had a higher risk for any infection (HR 2.8, 95% CI 1.4-5.3; P < .01) and deep infection (HR 2.9, 95% CI 1.3-6.3; P < .01). Survivorship free of infection was significantly higher at all time points for the cefazolin cohort.
DISCUSSION: In primary elbow arthroplasty, cefazolin administration was associated with significantly lower rates of PJI compared to non-cefazolin antibiotics, even in patients with a greater number of prior surgeries, which is known to increase the risk of PJI. For patients with penicillin or cephalosporin allergies, preoperative allergy testing or a cefazolin test dose should be considered before administering non-cefazolin alternatives.
1453741 Selective signalling PERFECT LIBERTY 26 Feb 1974 [2 April 1973] 8739/74 Heading G4H Equipment for collecting data concerning individual people (e.g. medical data) into a data collecting device, comprises a data keyboard, an I.D. card reader controlling a display for verification purposes, a transmission switch (e.g. manual) for causing transfer of the keyed data to the data collecting device, a printer for printing out entered information and means to indicate error upon receipt of an error signal from the data collecting device. The keys have lamps for indicating the entered data. Transfer to the data collecting device is achieved by sending an interrupt signal to it, to which it responds with read-out pulses to obtain the data, sending an end signal after receiving the data. Data is not transferred unless all the required data has been entered.
This is a randomized, prospective study where the diurnal variation of melatonin as well as sleep-related parameters (sleep duration and sleep quality) will be investigated with regards to light exposure during the hospital stay. Furthermore, it is investigated how psychological and cognitive functions are affected by light intervention and whether this is related to improved sleep or not. The study includes a total of 300 patients over the age of 65 who are cared for in an internal medicine or orthopedic surgery department at Skåne University Hospital in Malmö. The measurement period in the project is intended to be carried out during the period of October 2021-February 2022. Hospital rooms in the orthopedic department and in the medical department constitute the study environment. In all rooms, a biocentric lighting environment will be able to be created by activating a special lighting system. In these rooms, light will change dynamically both in spectral distribution and intensity during the day. During the day, color temperature and intensity are high (1000 lux and up to 6500 K) to decrease both intensity and color temperature during the evening. By weighing together spectral distribution and brightness, the circadian stimulus of the light environment can be calculated. The biocentric light provides a light with a high circadian stimulus during the morning and early afternoon. The biocentric light can be turned on (intervention) or off (control). When control setting, the standard normal light constitutes the light environment.

In all rooms included in the study, an accurate measurement of light conditions is carried out both with regard to spectral distribution and light intensity. Furthermore, patients will carry light meters to measure the actual amount of light to which patients are exposed. The study includes two arms, an intervention group and a control group. Patients who are assigned to one of the study rooms, and meet the inclusion criteria, will be asked to participate in the study. Patients are randomized to activate the biocentric light environment or standard light environment. The patients who are cared for in a biocentric light environment are included in the intervention group and those who are cared for in rooms with a standard light environment are included in the control group.

300 patients are to be included in the study. Surveys concerning alertness, sleep will be carried out. The frailty and a rapid test for delirium will be assessed. The patients will wear an actiwatch that records their sleep. For a small group of patients, also saliva melatonin will be collected every 4th hour from 7 pm to 11 am for two different nights 3 days apart. The results will be compared between the patients in the intervention group and the control group.
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
Patients and their partners will be randomized in a 2:1 fashion to two different treatment arms: A) standard of care in vitro fertilization (IVF) at the investigational institution as well as participating in an additional psychoeducational group or B) standard of care IVF at the investigational institution. The intervention group will consist of three additional evening visits for 1-1.5 hours per session. The sessions will include an interactive educational component addressing usual questions and concerns of IVF patients, such as reviewing common IVF myths, and also more information regarding treatment and technologies. Each session will also include teaching of coping strategies (such as awaiting the pregnancy test, how to cope with insensitive remarks from friends and family) as well as relaxation exercises, such as progressive muscle relaxation and deep breathing.

The patients will be consented at their new IVF visit and will take their initial assessments (FertiQoL, GAD-7, PHQ-9, the Connor-Davidson Resilience Scale, and a knowledge assessment) within 24 hours of the new visit. The patients will be assigned into groups based on when they are going through their IVF stimulations, so they will have similar experiences at similar times. Patients will take their final assessments on the third day after egg retrieval, regardless of group assignment.
NEW MATERIAL:A bonded material having the following properties. Appearance, white, pale yellow or yellow powder; solubility, easily soluble in water. EXAMPLE:Bonded ascorbic acid and geraniin of formula. USE:An agent suppressing lipid peroxide level in living body. Utilizable in the fields of medicine, food and cosmetic, etc. It has excellent safety and stability. PREPARATION:For example, 1-2mol of a tannin such as geraniin extracted from Geranium nepalense and 2-10mol of ascorbic acid are dissolved or dispersed in a mixture of water and alcohol and made to react with each other by heating at <=40 deg.C under stirring. The reaction mixture is treated by column chromatography to separate the objective material.
This is phase 3, multicenter, randomized, placebo-controlled double-blind, parallel study of subcutaneous injection of placebo and ustekinumab 45mg in Taiwanese and Korean patients with moderate to severe plaque psoriasis. Ustekinumab is an experimental medicine that is being tested to see if it may be useful in treating moderate to severe psoriasis. The patients will receive either ustekinumab or placebo at week 0 or week 4, and will be followed up through week 36. Patients who randomized (study drug assigned by chance) to placebo will cross over to ustekinumab 45mg group at week 12 and week 16 .The effectiveness of ustekinumab will be compared with placebo treated patients at week 12. Safety information will be collected through week 36. Patients randomized to ustekinumab will receive placebo at week 12 to maintain the blind and additional dose of 45mg at week 16. This study will be conducted in approximately 13 sites in South Korea and Taiwan and will include approximately 120 patients with approximately 60 patients in each country. This study is "blinded." This means that neither you nor your study doctor will know in which group you are placed. However, in case of medical emergency, your study doctor can quickly find out which treatment group you are in. You may get either ustekinumab or placebo (which looks like the medicine being studied but has no active ingredients) at the start of the study. All patients in the study will eventually receive Ustekinumab after week 12. Patients assigned to the ustekinumab will receive 45 mg subcutaneously at weeks 0, 4 and 16; and placebo at week 12. Patiens assigned to placebo will receive subcutaneous injections of placebo at weeks 0 and 4; then crossover to 45 mg of ustekinumab at weeks 12 and 16. Duration of study participation up to 36 weeks.